[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Poster Presentations: American Head and Neck Society
August 2006

P104 Radioimmunotherapy of Head and Neck Cancer Xenografts Using 131I-L19-SIP for Selective Targeting of Tumor Vasculature

Arch Otolaryngol Head Neck Surg. 2006;132(8):886. doi:10.1001/archotol.132.8.886-a

VU University Medical Center, Amsterdam, the Netherlands;

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich;

Research Laboratories of Schering AG, Berlin, Germany;

Istituto G. Gaslini, Genova, Italy

Objective: The human monoclonal antibody L19-SIP is directed against the extra domain B of fibronectin (ED-B), a marker of tumor angiogenesis. The potential of radioimmunotherapy (RIT) with L19-SIP was evaluated, either alone or in combination with the anti–epidermal growth factor receptor (EGFR) antibody cetuximab, for treatment of head and neck squamous cell carcinoma (HNSCC).

First Page Preview View Large
First page PDF preview
First page PDF preview
×